Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2018, Article ID 1952086, 5 pages
https://doi.org/10.1155/2018/1952086
Research Article

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy

Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil

Correspondence should be addressed to Rogério S. Parra; rb.psu.prch@arrapsr

Received 25 January 2018; Revised 4 April 2018; Accepted 12 April 2018; Published 8 May 2018

Academic Editor: Paolo Gionchetti

Copyright © 2018 Rogério S. Parra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Jacobs, R. Bissonnette, and L. C. Guenther, “Socioeconomic burden of immune-mediated inflammatory diseases — focusing on work productivity and disability,” The Journal of Rheumatology Supplement, vol. 88, pp. 55–61, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Holko, P. Kawalec, M. Mossakowska, and A. Pilc, “Health-related quality of life impairment and indirect cost of Crohn’s disease: a self-report study in Poland,” PLoS One, vol. 11, no. 12, article e0168586, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Armuzzi, G. van Assche, W. Reinisch et al., “Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 6, no. 4, pp. 492–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. J. F. Colombel, P. Rutgeerts, W. Reinisch et al., “Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis,” Gastroenterology, vol. 141, no. 4, pp. 1194–1201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Reinisch, J.-F. Colombel, W. J. Sandborn et al., “Factors associated with short- and long-term outcomes of therapy for Crohn’s disease,” Clinical Gastroenterology and Hepatology, vol. 13, no. 3, pp. 539–547.e2, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. R. S. Parra, M. R. Feitosa, J. J. Rocha, and O. Feres, “Inflammatory bowel diseases & disorders higher trough concentrations of infliximab are associated with clinical remission and mucosal healing in patients with inflammatory bowel disease,” Journal of Inflammatory Bowel Diseases & Disorders, vol. 1, p. 104, 2016. View at Google Scholar
  7. F. Beigel, M. Deml, F. Schnitzler et al., “Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies,” PLoS One, vol. 9, no. 6, article e99293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Vande Casteele, M. Ferrante, G. van Assche et al., “Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease,” Gastroenterology, vol. 148, no. 7, pp. 1320–1329.e3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Moore, G. Corbett, and A. C. Moss, “Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 10, no. 5, pp. 619–625, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Afonso, S. Lopes, R. Gonçalves et al., “Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays,” Alimentary Pharmacology and Therapeutics, vol. 44, no. 7, pp. 684–692, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Guyatt, A. Mitchell, E. J. Irvine et al., “A new measure of health status for clinical trials in inflammatory bowel disease,” Gastroenterology, vol. 96, no. 2, pp. 804–810, 1989. View at Publisher · View at Google Scholar · View at Scopus
  12. E. J. Irvine, B. Feagan, J. Rochon et al., “Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease,” Gastroenterology, vol. 106, no. 2, pp. 287–296, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. E. J. Irvine, Q. Zhou, and A. K. Thompson, “The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease,” American Journal of Gastroenterology, vol. 91, no. 8, pp. 1571–1578, 1996. View at Google Scholar
  14. M. C. Reilly, L. Gerlier, Y. Brabant, and M. Brown, “Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn’s disease,” Clinical Therapeutics, vol. 30, no. 2, pp. 393–404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Steenholdt, J. Brynskov, O. Ø. Thomsen et al., “Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial,” Gut, vol. 63, no. 6, pp. 919–927, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. A. Pontes, S. J. Miszputen, O. F. Ferreira-Filho, C. Miranda, and M. B. Ferraz, “Quality of life in patients with inflammatory bowel diseases: translation to Portuguese language and validation of the “Inflammatory Bowel Disease Questionnaire” (IBDQ),” Arquivos de Gastroenterologia, vol. 41, no. 2, pp. 137–143, 2004. View at Publisher · View at Google Scholar
  17. M. van der Have, K. S. van der Aalst, A. A. Kaptein et al., “Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis,” Journal of Crohn's and Colitis, vol. 8, no. 2, pp. 93–106, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Khanna, G. Zou, G. D'Haens et al., “A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity,” Alimentary Pharmacology and Therapeutics, vol. 41, no. 1, pp. 77–86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Steenholdt, J. Brynskov, O. Ø. Thomsen et al., “Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in Crohn’s disease,” Journal of Crohn's and Colitis, vol. 9, no. 11, pp. 1032–1042, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Y. Yoon, J. E. Shin, S. H. Park, D. I. Park, and J. M. Cha, “Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life,” Gut and Liver, vol. 11, no. 3, pp. 370–376, 2017. View at Publisher · View at Google Scholar · View at Scopus